These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7162517)

  • 21. Towards a recombinant vaccine against diphtheria toxin.
    Lobeck K; Drevet P; Léonetti M; Fromen-Romano C; Ducancel F; Lajeunesse E; Lemaire C; Ménez A
    Infect Immun; 1998 Feb; 66(2):418-23. PubMed ID: 9453589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies against diphtheria toxin fragment A. Characterization and introduction into living cells.
    Yoshimori T; Yamada M; Sugawa H; Mekada E; Uchida T; Okada Y
    Exp Cell Res; 1984 Apr; 151(2):344-53. PubMed ID: 6323199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of polyclonal and monoclonal antibody responses to cholera toxin by the synthetic peptide approach.
    Ghose AC; Karush F
    Mol Immunol; 1988 Mar; 25(3):223-30. PubMed ID: 3374493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of toxin neutralisation in test systems for diphtheria antibody assessment.
    Vandenberg J; van der Gun JW; Hendriksen CF
    Dev Biol Stand; 1999; 101():105-11. PubMed ID: 10566782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An enzyme-linked immunosorbent assay (ELISA) for the determination of diphtheria toxin antibodies.
    Svenson SB; Larsen K
    J Immunol Methods; 1977; 17(3-4):249-56. PubMed ID: 410890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunochemical studies of antitoxin produced in normal and allergic individuals hyperimmunized with diphtheria toxoid. II. A comparison between the immunological properties of precipitating and non-precipitating (skin-sensitizing) antitoxins.
    KUHNS WJ; PAPPENHEIMER AM
    J Exp Med; 1952 Apr; 95(4):375-92. PubMed ID: 14938507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation of a diphtheria toxin-pullulan conjugate that elicits good IgG antibody production with poor IgE synthesis.
    Yamaya S; Yamamoto A; Komiya T; Mizuguchi J; Matuhasi T
    Vaccine; 1990 Feb; 8(1):65-9. PubMed ID: 2107646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits.
    Caglar K; Aybay C; Ataoglu H
    APMIS; 2005 Apr; 113(4):256-63. PubMed ID: 15865606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avidity as a parameter for diphtheria vaccine efficacy.
    el-Kady EM
    Egypt J Immunol; 2004; 11(1):47-54. PubMed ID: 15724386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif.
    Brown F; Benkirane N; Limal D; Halimi H; Newman JF; Van Regenmortel MH; Briand JP; Muller S
    Vaccine; 1999 Aug; 18(1-2):50-6. PubMed ID: 10501234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antitoxic properties of monoclonal antibodies against diphtheria toxin].
    Zaĭtsev EM; Sviridov VV; Titova NG; Lebedev VS; Garipova MI
    Mol Gen Mikrobiol Virusol; 1985 Feb; (2):37-41. PubMed ID: 2432418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potency of a human monoclonal antibody to diphtheria toxin relative to equine diphtheria anti-toxin in a guinea pig intoxication model.
    Smith HL; Cheslock P; Leney M; Barton B; Molrine DC
    Virulence; 2016 Aug; 7(6):660-8. PubMed ID: 27070129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant.
    Rydell N; Sjöholm I
    Vaccine; 2004 Mar; 22(9-10):1265-74. PubMed ID: 15003656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen.
    Porro M; Costantino P; Viti S; Vannozzi F; Naggi A; Torri G
    Mol Immunol; 1985 Aug; 22(8):907-19. PubMed ID: 4047043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reconstitution of active diphtheria toxin based on a hexahistidine tagged version of the B-fragment produced to high yields in bacteria.
    Spilsberg B; Sandvig K; Wälchli S
    Toxicon; 2005 Dec; 46(8):900-6. PubMed ID: 16260019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibody against diphtheria toxin. Effect on toxin binding and entry into cells.
    Hayakawa S; Uchida T; Mekada E; Moynihan MR; Okada Y
    J Biol Chem; 1983 Apr; 258(7):4311-7. PubMed ID: 6187735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoprecipitation and partial characterization of diphtheria toxin-binding glycoproteins from surface of guinea pig cells.
    Proia RL; Hart DA; Holmes RK; Holmes KV; Eidels L
    Proc Natl Acad Sci U S A; 1979 Feb; 76(2):685-9. PubMed ID: 370834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A hybrid toxin containing fragment A from diphtheria toxin linked to the B protomer of cholera toxin.
    Mannhalter JW; Gilliland DG; Collier RJ
    Biochim Biophys Acta; 1980 Dec; 626(2):443-50. PubMed ID: 7213663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potency assay of diphtheria antitoxin in Vero cell microcultures.
    Sánchez Gómez R; Gallardo y Ramos R; González-Pacheco M
    Rev Latinoam Microbiol; 1996; 38(2):97-110. PubMed ID: 8986109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat.
    Matsuo K; Ishii Y; Quan YS; Kamiyama F; Mukai Y; Yoshioka Y; Okada N; Nakagawa S
    J Control Release; 2011 Jan; 149(1):15-20. PubMed ID: 20493218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.